Lindsey E. Roeker

3.6k total citations
58 papers, 651 citations indexed

About

Lindsey E. Roeker is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Lindsey E. Roeker has authored 58 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Genetics, 21 papers in Pathology and Forensic Medicine and 18 papers in Hematology. Recurrent topics in Lindsey E. Roeker's work include Chronic Lymphocytic Leukemia Research (42 papers), Lymphoma Diagnosis and Treatment (20 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Lindsey E. Roeker is often cited by papers focused on Chronic Lymphocytic Leukemia Research (42 papers), Lymphoma Diagnosis and Treatment (20 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Lindsey E. Roeker collaborates with scholars based in United States, United Kingdom and France. Lindsey E. Roeker's co-authors include Anthony R. Mato, Angela Dispenzieri, Meghan C. Thompson, Robert A. Kyle, Matthew S. Davids, Shaji Kumar, Andrew D. Zelenetz, S. Vincent Rajkumar, Mazyar Shadman and David A. Knorr and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lindsey E. Roeker

53 papers receiving 647 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lindsey E. Roeker United States 16 329 231 193 187 170 58 651
Deepesh Lad India 14 202 0.6× 265 1.1× 153 0.8× 125 0.7× 133 0.8× 131 622
Robert Delage Canada 18 305 0.9× 400 1.7× 178 0.9× 141 0.8× 139 0.8× 58 957
Abraham S. Kanate United States 17 129 0.4× 371 1.6× 376 1.9× 92 0.5× 197 1.2× 61 815
Karen Sweiss United States 13 188 0.6× 305 1.3× 145 0.8× 82 0.4× 55 0.3× 83 578
Sunday Ocheni Nigeria 15 175 0.5× 252 1.1× 176 0.9× 53 0.3× 102 0.6× 52 531
Francesca Gaia Rossi Italy 12 140 0.4× 180 0.8× 189 1.0× 60 0.3× 118 0.7× 32 615
Bradley Augustson Australia 11 186 0.6× 502 2.2× 312 1.6× 282 1.5× 127 0.7× 43 684
R Leblay France 9 380 1.2× 229 1.0× 294 1.5× 269 1.4× 263 1.5× 31 832
José‐Tomás Navarro Spain 17 305 0.9× 167 0.7× 583 3.0× 61 0.3× 571 3.4× 85 964
Sangeetha Venugopal United States 13 162 0.5× 336 1.5× 105 0.5× 254 1.4× 32 0.2× 44 583

Countries citing papers authored by Lindsey E. Roeker

Since Specialization
Citations

This map shows the geographic impact of Lindsey E. Roeker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsey E. Roeker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsey E. Roeker more than expected).

Fields of papers citing papers by Lindsey E. Roeker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsey E. Roeker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsey E. Roeker. The network helps show where Lindsey E. Roeker may publish in the future.

Co-authorship network of co-authors of Lindsey E. Roeker

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsey E. Roeker. A scholar is included among the top collaborators of Lindsey E. Roeker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsey E. Roeker. Lindsey E. Roeker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kwiatek, Michał, Guru Subramanian Guru Murthy, Marc Hoffmann, et al.. (2025). A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia. 25(7). 512–519. 1 indexed citations
2.
Roeker, Lindsey E., John M. Burke, Joanna Rhodes, et al.. (2025). Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI. Cancers. 17(5). 799–799. 1 indexed citations
3.
Valtis, Yannis K., Andriy Derkach, Ricardo Ortíz, et al.. (2024). Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood Advances. 8(22). 5806–5813. 1 indexed citations
4.
Roeker, Lindsey E., Jennifer A. Woyach, Chan Y. Cheah, et al.. (2024). Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 144(13). 1374–1386. 11 indexed citations
5.
Mitchell, Aaron Philip, Hannah E. Fuchs, Prabal K. De, et al.. (2024). Quality of Treatment Selection for Medicare Beneficiaries With Cancer. Journal of Clinical Oncology. 43(5). 524–535. 3 indexed citations
6.
Chin, Kuo‐Kai, Andriy Derkach, Christopher Famulare, et al.. (2024). HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML. Leukemia & lymphoma. 66(2). 270–278.
7.
Shadman, Mazyar, Sudeep Karve, Bruno Émond, et al.. (2024). Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma. 66(1). 44–53. 3 indexed citations
8.
Laracy, Justin, Nina Cohen, Elizabeth Robilotti, et al.. (2023). Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Haematologica. 108(11). 3058–3067. 6 indexed citations
9.
Roeker, Lindsey E., Maral DerSarkissian, Kellie Ryan, et al.. (2023). Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Advances. 7(16). 4291–4301. 10 indexed citations
10.
Roeker, Lindsey E., et al.. (2023). A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL). Cancers. 15(4). 1018–1018. 10 indexed citations
11.
12.
Ryan, Christine E., Matthew S. Davids, Sarang Abhyankar, et al.. (2022). MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Future Oncology. 18(33). 3689–3699. 15 indexed citations
13.
Kay, Neil E., Sameer A. Parikh, Kari G. Rabe, et al.. (2022). Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma. 64(2). 300–311. 2 indexed citations
14.
Lahoud, Oscar, Sean M. Devlin, Molly Maloy, et al.. (2021). Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation. Blood Advances. 5(14). 2879–2889. 18 indexed citations
15.
Roeker, Lindsey E., Meghan C. Thompson, & Anthony R. Mato. (2021). Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. Drugs. 82(2). 133–143. 6 indexed citations
16.
Roeker, Lindsey E., David A. Knorr, Melissa S. Pessin, et al.. (2020). Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 34(11). 3047–3049. 63 indexed citations
17.
Ujjani, Chaitra S., Anthony R. Mato, Brian T. Hill, et al.. (2020). <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. SHILAP Revista de lepidopterología. Volume 10. 1–5. 6 indexed citations
18.
Kim, Haesook T., Lindsey E. Roeker, Corey Cutler, et al.. (2019). Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(3). 529–539. 16 indexed citations
19.
Roeker, Lindsey E., Haesook T. Kim, Brett Glotzbecker, et al.. (2018). Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(1). 137–144. 32 indexed citations
20.
Grogan, Martha, Morie A. Gertz, Arleigh McCurdy, et al.. (2016). Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World Journal of Transplantation. 6(2). 380–380. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deepesh Lad Breakdown of academic impact, for papers by Robert Delage Breakdown of academic impact, for papers by Abraham S. Kanate Breakdown of academic impact, for papers by Karen Sweiss Breakdown of academic impact, for papers by Sunday Ocheni Breakdown of academic impact, for papers by Francesca Gaia Rossi Breakdown of academic impact, for papers by Bradley Augustson Breakdown of academic impact, for papers by R Leblay Breakdown of academic impact, for papers by José‐Tomás Navarro Breakdown of academic impact, for papers by Sangeetha Venugopal
Rankless by CCL
2026